Lazutka Juozas R, Daniūnaitė Kristina, Dedonytė Veronika, Popandopula Aistė, Žukaitė Karolina, Visockienė Žydrūnė, Šiaulienė Laura
Life Sciences Center, Vilnius University, Saulėtekio Al. 7, LT-10257 Vilnius, Lithuania.
Faculty of Medicine, Vilnius University, M. K. Čiurlionio St. 21, LT-03101 Vilnius, Lithuania.
Pharmaceuticals (Basel). 2024 Nov 16;17(11):1538. doi: 10.3390/ph17111538.
BACKGROUND/OBJECTIVES: Diabetes mellitus (DM) is a complex and heterogenous disease classified as a group of metabolic disorders characterized by chronic hyperglycemia resulting from defects in insulin secretion, insulin action, or both. It leads to various complications, some of which are macrovascular or microvascular complications, like diabetic polyneuropathy (DPN), having a profound impact on patients' quality of life. Oxidative stress (OS) is one of the significant mechanisms in the development and progression of DPN. Thus, targeting OS pathways by antioxidants, such as α-lipoic acid (ALA), could represent a promising therapeutic strategy for alleviating neuropathic symptoms. The aim of our study was to evaluate whether short-term (from 4 to 9 days) intravenous administration of ALA could cause any measurable improvement in subjects with DM.
Sixteen subjects with DM (six type 1 and ten type 2) and sixteen nondiabetic subjects matched by sex and age were recruited to this study. Only subjects with DM received treatment with ALA (600 mg daily). Pain intensity and biomarkers of DNA damage including plasma concentration of 8-hydroxy-2'-deoxyguanosine (8-OHdG), frequency of micronucleated lymphocytes (MN), and frequency of sister-chromatid exchanges (SCEs), were measured before and after the treatment with ALA.
Pain intensity and 8-OHdG levels were significantly lower in DM subjects after the ALA treatment than before the treatment. However, no changes in the frequency of SCEs and MN were observed.
Our results show some evidence that even a short-term intravenous treatment with ALA could be beneficial for diabetic subjects, reducing pain intensity and concentration of 8-OHdG in blood plasma.
背景/目的：糖尿病（DM）是一种复杂的异质性疾病，属于一组代谢紊乱疾病，其特征为胰岛素分泌缺陷、胰岛素作用缺陷或两者兼而有之导致的慢性高血糖。它会引发各种并发症，其中一些是大血管或微血管并发症，如糖尿病性多发性神经病变（DPN），对患者的生活质量有深远影响。氧化应激（OS）是DPN发生和发展的重要机制之一。因此，通过抗氧化剂（如α-硫辛酸（ALA））靶向OS途径可能是缓解神经病变症状的一种有前景的治疗策略。我们研究的目的是评估短期（4至9天）静脉注射ALA是否能使糖尿病患者有任何可测量的改善。
本研究招募了16名糖尿病患者（6名1型和10名2型）以及16名年龄和性别匹配的非糖尿病受试者。只有糖尿病患者接受ALA治疗（每日600毫克）。在ALA治疗前后测量疼痛强度以及DNA损伤的生物标志物，包括血浆8-羟基-2'-脱氧鸟苷（8-OHdG）浓度、微核淋巴细胞（MN）频率和姐妹染色单体交换（SCE）频率。
ALA治疗后，糖尿病患者的疼痛强度和8-OHdG水平显著低于治疗前。然而，未观察到SCE和MN频率的变化。
我们的结果显示，有证据表明即使短期静脉注射ALA对糖尿病患者也可能有益，可降低疼痛强度和血浆中8-OHdG的浓度。
